FDA Inspection 1231407 — Takeda Pharmaceuticals, Inc.

Takeda Pharmaceuticals, Inc. — FEI 3016418550

The FDA completed an inspection of Takeda Pharmaceuticals, Inc. on March 22, 2024 in Cambridge, MA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
March 22, 2024
Fiscal Year
2024
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Cambridge, MA (United States)

Additional Details

Risk Evaluation and Mitigation Strategies (REMS)